Duodenal Jejunal Bypass for Type 2 Diabetes (DJBD)

Clinical Evaluation of the Effect of Duodenal Jejunal Bypass on Type Two Diabetes in Non Obese Adults

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00487526

Acronym

DJBD

Enrollment

Registered

2007-06-18

Start date

2007-06-30

Completion date

Unknown

Last updated

2007-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Bypass, Duodenal jejunal, type 2 diabetes, non-obese adults

Brief summary

Study the effect of Duodenal jejunal bypass on human adults with type 2 diabetes.

Detailed description

Adults non obese ( BMI less than 34 ) will undergo duodenal jejunal bypass. The Outcome measures: Blood Sugar, Insulin,HbA1c, CCK,Gastrin, GIP1and 2, Ghrelin, Cholesterol, Triglycerides,FFA, C-Peptide.

Interventions

PROCEDUREduodenal jejunal bypass

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Adults age 20-65 * Clinical diagnosis of type 2 diabetes * Non obese with BMI less than 34. * Oral agents or insulin to control T2DM. * Inadequate control of diabetes as defined as HbA1c\>/7.5 * Understanding of the mechanisms of action of the treatment

Exclusion criteria

* Children with type 1 diabetes * Obese with BMI over 34 * Coagulopathy * Liver cirrhosis * Unable to comply with study requirements, follow-up or give valid consent * Currently pregnant * Previous upper abdominal surgery * Inabilty to tolerate general anesthesia

Design outcomes

Primary

Measure	Time frame
control of type 2 diabetes in non obese adults	two years

Secondary

Measure	Time frame
CCK FFA,Cholesterol,Ghrelin,C-peptide,HbA1c,Gastrin,GIP,Triglycerides,Insulin	2 years

Countries

Dominican Republic

Contacts

Primary ContactGeorge S Ferzli, MD, F.A.C.S

GFerzli@aol.com718-667-8100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026